Clinical trials: Pulmonary Hypertension, Primary, 4
Pulmonary Arterial Hypertension
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)
Researchers are looking for other ways to treat people in India with pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension (PH).
- Trial name
- NCT07600723
- Testing
- Sotatercept, Background PAH Therapy
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Pulmonary
Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years
This is an observational study to monitor the continued effectiveness of Ventavis (inhaled iloprost) in the long-term. The study observes the effects and the safety of Ventavis inhalation therapy over at least 2 years and up to 4…
- Trial name
- NCT00250640
- Testing
- Iloprost (Ventavis, BAYQ6256)
- Where
- 43 sites in France, Germany and 4 more
- Volunteers
- 106 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension
The study evaluates the effect of macitentan on right ventricular and hemodynamic properties in patients with symptomatic pulmonary arterial hypertension. Patients are treated with macitentan for 1 year.
- Trial name
- REPAIR (NCT02310672)
- Testing
- Macitentan
- Where
- 41 sites in United States, Australia and 10 more
- Volunteers
- 89 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in…
- Trial name
- ARTISAN (NCT05203510)
- Testing
- Parenteral Treprostinil, Oral Treprostinil
- Where
- 28 sites in United States
- Volunteers
- 52 people
- Sponsor
- United Therapeutics
Cardiovascular Disease, Pulmonary Arterial Hypertension
Effect of BIA 5 1058 on Cardiac Repolarization
The purpose is to evaluate the effect of single therapeutic (400 mg) and supratherapeutic (1200 mg) doses of BIA 5-1058 on the time-matched change from baseline in placebo-adjusted interval corrected (QT) for heart rate (HR)
- Conditions
- Cardiovascular Disease, Pulmonary Arterial Hypertension, Heart Failure
- Trial name
- NCT03489005
- Testing
- BIA 5-1058, Moxifloxacin 400 mg
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System
Ventavis it's a treatment for pulmonary hypertension, administered by an inhaler called I-Neb. In these patients, the non compliance of the treatment becomes its ineffective and increases the complications and mortality of the…
- Trial name
- Inventa (NCT01468545)
- Testing
- Iloprost (Ventavis inhaled, BAYQ6256)
- Where
- Spain
- Volunteers
- 38 people
- Sponsor
- Bayer
Pulmonary Hypertension Group 1 and 4 According to Nice Classification
NIMS- New Implantable Pump in Pulmonary Arterial Hypertension, a Safety Follow up
This observational study aims to chart patients which get their prostacyclin treatment via the subcutaneous LenusPro pump. How the surgical procedure is performed and the clinical follow-up of these patients.
- Trial name
- NCT01977014
- Where
- 8 sites in Denmark, Norway and 1 more
- Volunteers
- 40 people
- Sponsor
- NordicInfu Care AB
Pulmonary Arterial Hypertension
A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging
The purpose of the study is to assess the effects of selexipag on right ventricular (RV) function in participants with Pulmonary arterial hypertension (PAH).
- Trial name
- RESTORE (NCT04435782)
- Testing
- JNJ-67896049
- Where
- 35 sites in United States, Argentina and 13 more
- Volunteers
- 9 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
The primary objective of this study is to evaluate the effect of selexipag on the physical activity of patients with pulmonary arterial hypertension (PAH) in their daily life, by using a wearable wrist device (actigraph).
- Trial name
- TRACE (NCT03078907)
- Testing
- Selexipag
- Where
- 39 sites in United States, Austria and 8 more
- Volunteers
- 108 people
- Sponsor
- Actelion